Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.

This study suggests that the use of finasteride and dutasteride may be linked to a decreased risk of melanoma in white men aged ≥60 years who have benign or malignant prostate tumors.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

Both drugs lower DHT levels, with GI198745 being more effective.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.

In this study of men with androgenetic alopecia, dutasteride was shown to be more effective than finasteride in increasing hair count and reversing hair miniaturization over 24 weeks, with both treatments displaying similar side effect profiles.

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

This study found that both finasteride and dutasteride effectively increased hair thickness in women with androgenetic alopecia over three years, with dutasteride performing better in women under 50 at specific scalp sites.

This study found no statistically significant association between the use of 5α-reductase inhibitors and male breast cancer incidence.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This study found that the pharmacological inhibition of 5-α reductases with finasteride and dutasteride can reduce neurosteroid synthesis in glioblastoma-derived cell lines, potentially impacting GBM survival.

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

This study found that adding low-dose dutasteride to ongoing finasteride treatment significantly improved hair density in a patient with androgenetic alopecia.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

This study optimized the reaction conditions for the stereoselective hydrogenation of a compound used in manufacturing finasteride and dutasteride, improving the selectivity for the desired isomer.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that patients on dutasteride had $20.50 lower monthly medical costs compared to those on finasteride.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.

In this South Korean retrospective study, dutasteride improved hair growth more effectively than finasteride in men with androgenic alopecia, and had a similar or possibly lower rate of adverse events, suggesting it as a viable treatment option.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.